Xtx Topco LTD Protalix Bio Therapeutics, Inc. Transaction History

Xtx Topco LTD

$1.81 Billion
Q1 2025

A detailed history of Xtx Topco LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Xtx Topco LTD holds 41,826 shares of PLX stock, worth $67,339. This represents 0.01% of its overall portfolio holdings.

Number of Shares

41,826

Holding current value

$67,339

% of portfolio

0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 07, 2025	BUY	$1.88 - $2.69 $78,632 - $112,511	41,826 New	41,826 $107,000
Q3 2024 Nov 14, 2024	BUY	$0.9 - $1.17 $31,552 - $41,017	35,058 New	35,058 $35,000
Q4 2023 Feb 13, 2024	SELL	$1.34 - $1.85 $87,398 - $120,662	-65,223 Reduced 77.67%	18,750 $33,000
Q3 2023 Nov 13, 2023	SELL	$1.49 - $2.02 $129,488 - $175,548	-86,905 Reduced 50.86%	83,973 $139,000
Q2 2023 Aug 14, 2023	BUY	$2.0 - $3.36 $273,628 - $459,695	136,814 Added 401.64%	170,878 $341,000
Q1 2023 May 12, 2023	BUY	$1.37 - $2.16 $46,667 - $73,578	34,064 New	34,064 $71,000
Q4 2021 Feb 11, 2022	SELL	$0.81 - $1.33 $16,616 - $27,283	-20,514 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$1.31 - $1.87 $4,409 - $6,294	3,366 Added 19.63%	20,514 $27,000
Q2 2021 Aug 12, 2021	BUY	$1.86 - $6.22 $31,895 - $106,660	17,148 New	17,148 $33,000

Others Institutions Holding PLX

# of Institutions

Shares Held

8.27M

Call Options Held

227K

Put Options Held

54.5K

Jim Simons Renaissance Technologies LLC | New York, Ny

1.19M
Shares

$1.91 Million
0.0% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

963K
Shares

$1.55 Million
0.0% of portfolio
Susquehanna International Group, LLP Bala Cynwyd, PA

859K
Shares

$1.38 Million
0.0% of portfolio
Northern Trust Corp Chicago, IL

685K
Shares

$1.1 Million
0.0% of portfolio
Marshall Wace, LLP London, X0

615K
Shares

$990,286
0.0% of portfolio

View Full List

About Protalix BioTherapeutics, Inc.

Ticker PLX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,753,400
Market Cap $80.1M
Description
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...

More about PLX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account